Dianthus Therapeutics Inc

DNTH

Add to Watchlist

85.130USD

-0.610-0.71%

Market hours （ET）Quotes delayed by 15 min

Dianthus Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

46 / 383

Overall Ranking

144 / 4487

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Dianthus Therapeutics Inc Highlights

StrengthsRisks

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.04M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.04M.

Undervalued

The company’s latest PE is -20.27, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 54.50M shares, increasing 8.89% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 124.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.03.

Analyst Rating

Based on 16 analysts

Strong Buy

Current Rating

126.154

Target Price

+44.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Dianthus Therapeutics Inc is 6.11, ranking 282 out of 383 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 463.00K, representing a year-over-year decrease of 60.19%, while its net profit experienced a year-over-year decrease of 38.37%.

Score

Industry at a Glance

Previous score

6.11

Change

0



Financials

7.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.24

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Dianthus Therapeutics Inc is 6.72, ranking 222 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -20.27, which is -120.45% below the recent high of 4.15 and -66.04% above the recent low of -33.66.

Score

Industry at a Glance

Previous score

6.72

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/383

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Dianthus Therapeutics Inc is 9.00, ranking 17 out of 383 in the Biotechnology & Medical Research industry. The average price target is 65.00, with a high of 100.00 and a low of 46.00.

Score

Industry at a Glance

Previous score

9.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Dianthus Therapeutics Inc is 7.14, ranking 142 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 94.16 and the support level at 79.66, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.20

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-13

The current institutional shareholding score of Dianthus Therapeutics Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 99.70%, representing a quarter-over-quarter decrease of 0.93%. The largest institutional shareholder is Steven Cohen, holding a total of 2.98M shares, representing 5.45% of shares outstanding, with 17.84% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

6.32M

+7.37%

Point72 Asset Management, L.P.

Star Investors

2.98M

+155.70%

Wellington Management Company, LLP

2.50M

-2.89%

Octagon Capital Advisors LP

2.42M

--

Fairmount Funds Management LLC

2.14M

--

Avidity Partners Management LP

2.10M

--

BlackRock Institutional Trust Company, N.A.

1.74M

+41.48%

TCG Crossover Management, LLC

1.68M

--

RA Capital Management, LP

1.61M

-43.78%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dianthus Therapeutics Inc is 5.74, ranking 39 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Dianthus Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Dianthus Therapeutics Inc

DNTH

7.34 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment